Presentation is loading. Please wait.

Presentation is loading. Please wait.

Olumacostat glasaretil, a novel topical sebum inhibitor, in the treatment of acne vulgaris: A phase IIa, multicenter, randomized, vehicle-controlled study 

Published byYuliana Yuwono Modified over 5 years ago

Similar presentations

Presentation on theme: "Olumacostat glasaretil, a novel topical sebum inhibitor, in the treatment of acne vulgaris: A phase IIa, multicenter, randomized, vehicle-controlled study "— Presentation transcript:

1 Olumacostat glasaretil, a novel topical sebum inhibitor, in the treatment of acne vulgaris: A phase IIa, multicenter, randomized, vehicle-controlled study  Robert Bissonnette, MD, Yves Poulin, MD, Janice Drew, MPH, Hans Hofland, PhD, Jerry Tan, MD  Journal of the American Academy of Dermatology  Volume 76, Issue 1, Pages (January 2017) DOI: /j.jaad Copyright © Terms and Conditions

2 Fig 1 Acetyl coenzyme A carboxylase (ACC) effect on sebum production. CoA, Coenzyme A; HMG CoA, 3-hydroxy-3-methyl-glutaryl-coenzyme A; OG, olumacostat glasaretil; TOFA, 5-(tetradecyloxy)-2-furancarboxylic acid. Journal of the American Academy of Dermatology  , 33-39DOI: ( /j.jaad ) Copyright © Terms and Conditions

3 Fig 2 Patient disposition. IGA, Investigator global assessment. *One subject in the vehicle group had no postbaseline efficacy assessments. The subject was not included in analyses of changes from baseline in lesion counts, but was included in analyses of changes in IGA score for which the subject was considered to have no change in IGA score. Journal of the American Academy of Dermatology  , 33-39DOI: ( /j.jaad ) Copyright © Terms and Conditions

4 Fig 3 Change in lesion count. A, The absolute change in lesion count (ie, the change in the number of lesions). B, The percent change in lesion count. Journal of the American Academy of Dermatology  , 33-39DOI: ( /j.jaad ) Copyright © Terms and Conditions

5 Fig 4 Change in investigator global assessment score from baseline at week 12. IGA, Investigator global assessment. Journal of the American Academy of Dermatology  , 33-39DOI: ( /j.jaad ) Copyright © Terms and Conditions

Download ppt "Olumacostat glasaretil, a novel topical sebum inhibitor, in the treatment of acne vulgaris: A phase IIa, multicenter, randomized, vehicle-controlled study "

Similar presentations

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study  Jerry.

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study  Jerry.
A randomized study of the efficacy and safety of injectable poly-L-lactic acid versus human-based collagen implant in the treatment of nasolabial fold.

A randomized study of the efficacy and safety of injectable poly-L-lactic acid versus human-based collagen implant in the treatment of nasolabial fold.
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial  Diamant.

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial  Diamant.
Lauren Kwa, BA, Jonathan I. Silverberg, MD, PhD, MPH 

Lauren Kwa, BA, Jonathan I. Silverberg, MD, PhD, MPH 
The impact of chocolate consumption on acne vulgaris in college students: A randomized crossover study  Gregory R. Delost, DO, Maria E. Delost, PhD, Jenifer.

The impact of chocolate consumption on acne vulgaris in college students: A randomized crossover study  Gregory R. Delost, DO, Maria E. Delost, PhD, Jenifer.
Yul W. Yang, MD, PhD, David J. DiCaudo, MD 

Yul W. Yang, MD, PhD, David J. DiCaudo, MD 
Efficacy of simvastatin in plaque psoriasis: A pilot study

Efficacy of simvastatin in plaque psoriasis: A pilot study
Elana Putterman, BS, Leslie Castelo-Soccio, MD, PhD 

Elana Putterman, BS, Leslie Castelo-Soccio, MD, PhD 
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.
OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild.

OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild.
Two randomized, double-blind, placebo-controlled studies of fluticasone propionate lotion 0.05% for the treatment of atopic dermatitis in subjects from.

Two randomized, double-blind, placebo-controlled studies of fluticasone propionate lotion 0.05% for the treatment of atopic dermatitis in subjects from.
The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study  Hsien-Yi Chiu, MD, Tsen-Fang.

The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study  Hsien-Yi Chiu, MD, Tsen-Fang.
Treatment of notalgia paresthetica with botulinum toxin A: A double-blind randomized controlled trial  Catherine Maari, MD, FRCPC, Philippe Marchessault,

Treatment of notalgia paresthetica with botulinum toxin A: A double-blind randomized controlled trial  Catherine Maari, MD, FRCPC, Philippe Marchessault,
A randomized, double-blind, vehicle-controlled, bilateral comparison trial of bexarotene gel 1% versus vehicle gel in combination with narrowband UVB.

A randomized, double-blind, vehicle-controlled, bilateral comparison trial of bexarotene gel 1% versus vehicle gel in combination with narrowband UVB.
Brad A. Yentzer, MD, Ali Alikhan, BS, Hoa Teuschler, MS, Lisa L

Brad A. Yentzer, MD, Ali Alikhan, BS, Hoa Teuschler, MS, Lisa L
The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis  Alan Menter, MD, Jennifer C. Cather, MD, Diane.

The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis  Alan Menter, MD, Jennifer C. Cather, MD, Diane.
Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled.

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled.
Assessing adherence with phototherapy protocols

Assessing adherence with phototherapy protocols
Effect of appearance-based education compared with health-based education on sunscreen use and knowledge: A randomized controlled trial  William Tuong,

Effect of appearance-based education compared with health-based education on sunscreen use and knowledge: A randomized controlled trial  William Tuong,
Pharmacy costs of specialty medications for plaque psoriasis in the United States  Eric J. Yang, BS, Kristen M. Beck, MD, Sahil Sekhon, MD, Tina Bhutani,

Pharmacy costs of specialty medications for plaque psoriasis in the United States  Eric J. Yang, BS, Kristen M. Beck, MD, Sahil Sekhon, MD, Tina Bhutani,

Similar presentations

Ads by Google